Form 483

King Pharmaceuticals LLC Form 483, 2011-03-16

FDA issued a Form 483 to King Pharmaceuticals LLC on 2011-03-16 with 9 public-safe observations.

483· Form 483 issued9 observations

King Pharmaceuticals LLC · Rochester, United States · Issued March 16, 2011

Overview

  • 9 public-safe observations are available for this inspection.
  • 8 structured CFR citations are represented.
  • 3 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

16 Mar 2011
21 CFR 211.22(d)

Procedures not in writing, fully followed

Cited by Rebecca E Dombrowski, Sarah M Napier, Sanket N Patel

16 Mar 2011
21 CFR 211.42(c)

Defined areas of adequate size for operations

Cited by Rebecca E Dombrowski, Sarah M Napier, Sanket N Patel

16 Mar 2011
21 CFR 211.67(b)

Written procedures fail to include

Cited by Rebecca E Dombrowski, Sarah M Napier, Sanket N Patel

16 Mar 2011
21 CFR 211.67(b)

Written procedures not established/followed

Cited by Rebecca E Dombrowski, Sarah M Napier, Sanket N Patel

16 Mar 2011
21 CFR 211.84(d)(3)

Testing Containers & Closures Conformity with Specs

Cited by Rebecca E Dombrowski, Sarah M Napier, Sanket N Patel

Inspected site

KPKing Pharmaceuticals LLCRochester, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 211.67(b)Cited across public-safe Form 483 observations2x
21 CFR 211.100(b)Cited across public-safe Form 483 observations1x
21 CFR 211.160(b)Cited across public-safe Form 483 observations1x
21 CFR 211.192Cited across public-safe Form 483 observations1x
21 CFR 211.198(a)Cited across public-safe Form 483 observations1x
21 CFR 211.22(d)Cited across public-safe Form 483 observations1x
21 CFR 211.42(c)Cited across public-safe Form 483 observations1x
21 CFR 211.84(d)(3)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 9 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere